Lilly’s Weight-Loss Pill Moves Ahead After Pivotal Trial (3)

Eli Lilly & Co.’s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval.

It’s the second of two pivotal trials Lilly plans to use to show global health regulators that its drug, called orforglipron, is safe and effective for patients with obesity. The first trial disappointed investors earlier this month who had been expecting higher weight loss and lower rates of side effects.

Weight-loss injections from Lilly and rival Novo Nordisk A/S have revolutionized the way obesity is treated, but pills are the ...